Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Resmed Inc.
Nieuws
Resmed Inc.
RMD
NYS
: RMD
| ISIN: US7611521078
7/06/2023
214,77 USD
(-3,25%)
(-3,25%)
7/06/2023
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Dividend
Technische analyse
TA
Toon enkel gratis nieuws
25 mei 2023 ·
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
· Persbericht
2 mei 2023 ·
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
· Persbericht
30 maart 2023 ·
ResMed Chief Administrative Officer and Global General Counsel to Retire
· Persbericht
13 maart 2023 ·
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
· Persbericht
26 januari 2023 ·
ResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair Emeritus
· Persbericht
22 november 2022 ·
ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
· Persbericht
4 september 2022 ·
Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports
· Persbericht
28 juni 2022 ·
ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care
· Persbericht
14 juni 2022 ·
ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions
· Persbericht
25 mei 2022 ·
ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference
· Persbericht
18 mei 2022 ·
Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study
· Persbericht
5 mei 2022 ·
ResMed Announces Leadership Change
· Persbericht
28 april 2022 ·
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022
· Persbericht
27 april 2022 ·
ResMed Announces Participation in the 24th Annual Macquarie Australia Conference
· Persbericht
7 april 2022 ·
ResMed to Report Third Quarter Fiscal 2022 Earnings on April 28, 2022
· Persbericht
17 maart 2022 ·
ResMed Announces Participation in the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
· Persbericht
14 maart 2022 ·
ResMed’s Global Sleep Surveys Reveal What’s Keeping Us Up at Night; Aim to Bring Awareness to the State of Sleep Health for World Sleep Day
· Persbericht
10 maart 2022 ·
ResMed Announces Participation in the Oppenheimer 32nd Annual Healthcare Conference
· Persbericht
1 februari 2022 ·
ResMed Welcomes Urvashi Tyagi as New Chief Technology Officer
· Persbericht
8 september 2021 ·
People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe